These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 825590)

  • 1. Clinical evaluation of amikacin in treatment of infections due to gram-negative aerobic bacilli.
    Mathias RG; Ronald AR; Gurwith MJ; McCullough DW; Stiver HG; Berger J; Cates CY; Fox LM; Lank BA
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-401. PubMed ID: 825590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP; Louie TJ; O'Keefe P; Gorbach SL; Bartlett JG
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Amikacin in a hospital for children: microbiological and clinical studies.
    Marget W; Reindke B; Versmold H
    J Infect Dis; 1976 Nov; 134 SUPPL():S412-9. PubMed ID: 825592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of results of clinical trials with amikacin.
    Gooding PG; Berman E; Lane AZ; Agre K
    J Infect Dis; 1976 Nov; 134 SUPPL():S441-5. PubMed ID: 792360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amikacin therapy for serious gram-negative infection.
    Pollock AA; Berger SA; Richmond AS; Simberkoff MS; Rahal JJ
    JAMA; 1977 Feb; 237(6):562-4. PubMed ID: 576282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amikacin in treatment of infections caused by gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results.
    Daikos GK; Kosmidis JC; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S286-90. PubMed ID: 993623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM; McGee ZA; Alford RH
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary clinical trial with amikacin in chronic recurrent gram-negative bacterial infections refractory to other antimicrobial agents.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S381-3. PubMed ID: 993631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1985 Aug; 16(2):227-34. PubMed ID: 3934125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic.
    Lode H; Grunert K; Koeppe P; Langmaack H
    J Infect Dis; 1976 Nov; 134 SUPPL():S316-22. PubMed ID: 825589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amikacin Therapy of Urinary tract infections.
    Cox CE
    J Infect Dis; 1976 Nov; 134 SUPPL():S362-8. PubMed ID: 792358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF; Maslow MJ; Leibowitz RE; Pollock AA; Hanna BA; Schaefler S; Simberkoff MS; Rahal JJ
    J Infect Dis; 1985 Feb; 151(2):295-300. PubMed ID: 3918124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin in obstetric, gynecologic, and neonatal infections: laboratory and clinical studies.
    Mazzei T; Paradiso M; Nicoletti I; Periti P
    J Infect Dis; 1976 Nov; 134 SUPPL():S374-9. PubMed ID: 993629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amikacin in the treatment of gram-negative bronchopulmonary infections.
    Van Der Straeten M; Pauwels R; Pijck J; Van Nimmen L; Kluyskens P; Soep H
    J Infect Dis; 1976 Nov; 134 SUPPL():S391-3. PubMed ID: 1086876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term amikacin use. Effects on aminoglycoside susceptibility patterns of gram-negative bacilli.
    Moody MM; de Jongh CA; Schimpff SC; Tillman GL
    JAMA; 1982 Sep; 248(10):1199-202. PubMed ID: 6809965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hospita-acquired infections with amikacin.
    Doughty SC; Martin RR; Greenberg SB
    Am J Med; 1977 Jun; 62(6):889-93. PubMed ID: 868903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amikacin therapy of infections in neutropenic patients.
    Valdivieso M; Feld R; Rodriguez V; Bodey GP
    Am J Med Sci; 1975; 270(3):453-63. PubMed ID: 1108649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amikacin therapy of gram-negative bacteremia and meningitis. Treatment in diseases due to multiple resistant bacilli.
    Sklaver AR; Greenman RL; Hoffman TA
    Arch Intern Med; 1978 May; 138(5):713-6. PubMed ID: 348135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms.
    Yu VL; Rhame FS; Pesanti EL; Axline SG
    JAMA; 1977 Aug; 238(9):943-7. PubMed ID: 328950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.